Euphorbiasteroid

CAS No. 28649-59-4

Euphorbiasteroid( —— )

Catalog No. M18366 CAS No. 28649-59-4

Euphorbiasteroid (25-50 μM) decreased differentiation of 3T3-L1 cells via reduction of intracellular triglyceride (TG) accumulation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 73 In Stock
2MG 31 In Stock
5MG 48 In Stock
10MG 65 In Stock
25MG 117 In Stock
50MG 166 In Stock
100MG 247 In Stock
200MG 367 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Euphorbiasteroid
  • Note
    Research use only, not for human use.
  • Brief Description
    Euphorbiasteroid (25-50 μM) decreased differentiation of 3T3-L1 cells via reduction of intracellular triglyceride (TG) accumulation.
  • Description
    Euphorbiasteroid (25-50 μM) decreased differentiation of 3T3-L1 cells via reduction of intracellular triglyceride (TG) accumulation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    28649-59-4
  • Formula Weight
    552.66
  • Molecular Formula
    C32H40O8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C1[C@@]2(O1)[C@H]([C@@H]1[C@@](C(=O)/C(=C\[C@@H]3[C@H](CC2)C3(C)C)/C)(C[C@@H]([C@@H]1OC(=O)Cc1ccccc1)C)OC(=O)C)OC(=O)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Park SJ, et al. Cell Biochem Funct. 2015 Jun;33(4):220-5.
molnova catalog
related products
  • Total ginkgolic acid

    Total ginkgolic acid

  • Sarmazenil

    Sarmazenil (Ro 15-3505) is a partial inverse agonist at the benzodiazepine receptor with pro-convulsant properties and is used in the study of chronic hepatic encephalopathy (HE).

  • Rhamnazin

    Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.